Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Pharmaceutical Insights: Plinabulin's R&D Progress and its Mechanism of Action on Drug Target
10 October 2023
This article summarized the latest R&D progress of Plinabulin, the Mechanism of Action for Plinabulin, and the drug target R&D trends for Plinabulin.
Valuable Targets
4 min read
Analysis on the Research Progress of Chk1 inhibitor
10 October 2023
Chk1, also known as checkpoint kinase 1, is a crucial protein kinase involved in the regulation of cell cycle progression and DNA damage response in the human body.
Drug Insights
4 min read
Exploring Pindolol's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
10 October 2023
This article summarized the latest R&D progress of Pindolol, the Mechanism of Action for Pindolol, and the drug target R&D trends for Pindolol.
Latest Hotspot
3 min read
The FDA grants Merck accelerated consideration for their new BLA for the Activin Signaling Inhibitor, Sotatercept
10 October 2023
Merck has declared that a fresh BLA for sotatercept has been approved for accelerated assessment by the U.S. FDA.
Drug Insights
4 min read
Decoding Pertuzumab: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
10 October 2023
This article summarized the latest R&D progress of Pertuzumab, the Mechanism of Action for Pertuzumab, and the drug target R&D trends for Pertuzumab.
Advanced Tech.
8 min read
Inventory of GPCR Targeted Drugs Applying for Listing (I)
10 October 2023
This article will review currently applied listed GPCR-targeting drugs, and the associated popular GPCR class targets and drug development opportunities worth paying attention to.
Drug Insights
4 min read
Deep Scientific Insights on Panitumumab's R&D Progress, Mechanism of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Panitumumab, the Mechanism of Action for Panitumumab, and the drug target R&D trends for Panitumumab.
Latest Hotspot
3 min read
First Participant Administered in Stage 1b Clinical Evaluation of STK-012, Intended for Therapy of Solid Tumors
9 October 2023
STK-012 is designed specifically to activate antigen-triggered T cells, crucial for powerful anti-cancer effects, while avoiding broader activation of other lymphocytes, such as NK cells related to IL-2 toxicity.
Drug Insights
4 min read
An In-depth Analysis of Olopatadine hydrochloride's R&D Progress
9 October 2023
This article summarized the latest R&D progress of Olopatadine hydrochloride, the Mechanism of Action for Olopatadine hydrochloride, and the drug target R&D trends for Olopatadine hydrochloride.
R&D Pipeline
8 min read
Discussing the invalidation of parts of Upadacitinib patents and the dissolution of Reistone Biopharma, a subsidiary of Jiangsu Hengrui Pharmaceutical
9 October 2023
On the night of September 14, market rumors indicated that Jiangsu Hengrui Pharmaceutical was about to dissolve its subsidiary, Reistone Biopharma.
Drug Insights
4 min read
Norfloxacin: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
9 October 2023
This article summarized the latest R&D progress of Norfloxacin, the Mechanism of Action for Norfloxacin, and the drug target R&D trends for Norfloxacin.
Latest Hotspot
4 min read
ELAHERE® Demonstrates Advantage in Overall and Progression-Free Survival in Ovarian Cancer
9 October 2023
ImmunoGen Inc. shared outcomes from two assessments of the MIRASOL Phase 3 trial. The trial evaluated safety and effectiveness of ELAHERE® in platinum-resistant ovarian cancer patients positive for the folate receptor alpha, versus chemotherapy.